Medtronic (BSP:MDTC34) EBIT: R$36,318 Mil (TTM As of Apr. 2026)


BSP:MDTC34 Medtronic PLC BSP:MDTC34
67 GF Score
Price R$209.95
GF Value R$260.36
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Medtronic EBIT?

Medtronic BSP:MDTC34 +2.96% 67 EBIT is R$36,318 Mil as of Apr. 2026. GuruFocus rates BSP:MDTC34 with a GF Score™ of 67/100 and a GF Value™ of R$260.36 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Medtronic's earnings before interest and taxes (EBIT) for the three months ended in Apr. 2026 was R$10,118 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Apr. 2026 was R$36,318 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medtronic's annualized ROC % for the quarter that ended in Apr. 2026 was 7.02%. Medtronic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was 58.52%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medtronic's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was 5.73%.


Medtronic  (BSP:MDTC34) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medtronic's annualized ROC % for the quarter that ended in Apr. 2026 is calculated as:

ROC % (Q: Apr. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2026 ) + Invested Capital (Q: Apr. 2026 ))/ count )
=40532.964 * ( 1 - 31.35% )/( (407222.276 + 385677.282)/ 2 )
=27825.879786/396449.779
=7.02 %

where

Invested Capital(Q: Jan. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=487761.426 - 35844.347 - ( 44694.803 - max(0, 50623.542 - 128336.944+44694.803))
=407222.276

Invested Capital(Q: Apr. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=468293.649 - 36203.809 - ( 46412.558 - max(0, 58685.206 - 124775.279+46412.558))
=385677.282

Note: The Operating Income data used here is four times the quarterly (Apr. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Medtronic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Apr. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2026  Q: Apr. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=40472.556/( ( (38275.556 + max(34036.935, 0)) + (37336.436 + max(28678.128, 0)) )/ 2 )
=40472.556/( ( 72312.491 + 66014.564 )/ 2 )
=40472.556/69163.5275
=58.52 %

where Working Capital is:

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(33903.644 + 33637.064 + 16101.433) - (35844.347 + 0 + 13760.859)
=34036.935

Working Capital(Q: Apr. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(33440.198 + 29956.739 + 14965.784) - (36203.809 + 0 + 13480.784)
=28678.128

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medtronic's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Apr. 2026 )
=36318.125/634022.067
=5.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medtronic EBIT Related Terms


Medtronic EBIT Historical Data

* Premium members only.

The historical data trend for Medtronic's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medtronic EBIT Chart

Medtronic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28,861.03 30,129.00 28,502.28 36,810.21 34,487.25

Medtronic Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,309.37 8,178.07 9,571.33 8,450.59 10,118.14

BSP:MDTC34 vs SYK, BSX, EW: EBIT Comparison

For the Medical Devices subindustry, Medtronic's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medtronic EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medtronic's EV-to-EBIT falls into.


BSP:MDTC34
67GF Score
Medtronic PLC BSP:MDTC34
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medtronic EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$36,318 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of R$36,318 Mil mean?
Medtronic (BSP:MDTC34) has a EBIT of R$36,318 Mil as of Apr. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medtronic.
Is Medtronic's EBIT too high?
Medtronic's current EBIT is R$36,318 Mil. Overall, Medtronic has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's EBIT compare to SYK and BSX?
Medtronic's EBIT of R$36,318 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medtronic. Medtronic's current EBIT is R$36,318 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (BSP:MDTC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$260.36, compared to a current price of R$209.95 — trading 19.4% below its estimated fair value. The current EBIT is R$36,318 Mil. Medtronic's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Medtronic (BSP:MDTC34), the current EBIT is R$36,318 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medtronic (BSP:MDTC34) Overvalued in 2026?

Based on GuruFocus' analysis, Medtronic stock appears to be undervalued. The current stock price of R$209.95 is trading 19.4% below its estimated GF Value™ of R$260.36. GuruFocus considers Medtronic to be Modestly Undervalued.

Key valuation signals for BSP:MDTC34:

  • EBIT: R$36,318 Mil
  • GF Value™: R$260.36 vs. price of R$209.95 (19.4% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the BSP:MDTC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medtronic Business Description

Address Parkmore Business Park West, Building Two, Galway, IRL
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
67GF Score

Get the complete analysis for BSP:MDTC34

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$209.95
Price
R$260.36
GF Value